Atorvastatin Calcium Tablets – 10 mg 30 Bottle Label (Atorvastatin 10 mg 30 Bottle Label)
Atorvastatin Calcium Tablet, Film Coated
Product Images NDC 16729-044
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 16729-044). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Accord Healthcare Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Atorvastatin Calcium Tablets – 20 mg 30 Bottle Carton (Atorvastatin 20 mg 30 Bottle Label)
Atorvastatin Calcium Tablets – 40 mg 30 Bottle Label (Atorvastatin 40 mg 30 Bottle Label)
Atorvastatin Calcium Tablets – 80 mg 30 Bottle Carton (Atorvastatin 80 mg 30 Bottle Label)
This is a medication for lowering cholesterol levels in the body. Each coated tablet contains Atorvastatin Calcium USP equivalent to Atorvastatin 80 mg. The medication is stored in a cool and dry place and dispensed in tight containers. The dosage and usage information can be found on the package insert. The medication is manufactured by Accord Healthcare, Inc. in Durham, NC, and by Intas Pharmaceuticals Limited in Ahmedabad, India. The prescription drug is sold in a package of 30 tablets and should be kept in an area that is dark and vermin free. The remaining characters are unreadable.*
Figure (Atorvastatin Calcium Figure 1)
Figure (Atorvastatin Calcium Figure 2)
This appears to be a graph or chart representing data on a study of placebo and Atorvastatin (a drug used to treat high cholesterol). The x-axis indicates the time to the first primary endpoint over 4 years, and the y-axis shows the cumulative hazard percentage. The data suggests that Atorvastatin may be effective in reducing the primary endpoint compared to placebo, with a Hazard Ratio of 0.63 and a statistically significant p-value of 0.001.*
Figure (Atorvastatin Calcium Figure 3)
This is a clinical data report showing the percentages of subjects experiencing events of a major cardiovascular endpoint for different dosages of Atorvastatin (10mg and 80 mg) over a period of 5 years. The report highlights a significant decrease in the risk of experiencing the endpoint for those taking 80 mg of Atorvastatin compared to those taking 10mg, as evidenced by the hazard ratio (HR) of 0.78 with a p-value of 0.0002.*
Chemical Structure (Atorvastatin Calcium Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
